Haifa, Israel — November 20, 2025 — Leads & Copy — Minovia Therapeutics Ltd., a clinical-stage biotechnology company, will present data on its mitochondrial augmentation technology in myelodysplastic syndrome (MDS) at the 67th American Society of Hematology’s Annual Meeting and Exposition, Dec. 6-9 in Orlando, FL.
Research teams from Memorial Sloan Kettering Cancer Center (MSK) and Shaare Zedek Medical Center (SZMC) collected the data. The findings will be presented in an oral presentation on Saturday, Dec. 6, at 2PM ET and during a workshop titled “Mitochondria and metabolism – clinical trials,” on Friday, Dec. 5, at 5:10PM ET.
Dr. Omar Abdel-Wahab, the principal investigator, will present the MSK team’s progress in preclinical studies using an MDS animal model. The SZMC team will share findings from a Phase 1b clinical trial of MNV-201, Minovia’s lead product, in low-risk MDS patients.
MNV-201 has demonstrated a high safety and tolerability profile in the seven patients who have received the treatment. The patients showed no anti-mitochondrial antibodies or drug-related adverse events. One patient experienced transfusion independence with rising hemoglobin levels sustained for over 10 months and also showed improvement in blood-based biomarkers of mitochondrial function.
Minovia Co-founder and CEO Dr. Natalie Yivgi-Ohana said the data for MNV-201 is encouraging. She expressed gratitude to the MSK and SZMC teams for spearheading the research to demonstrate its utility in this indication.
Dr. Yivgi-Ohana added that the company is excited about the possibility that mitochondrial augmentation of hematopoietic stem and progenitor cells may delay the progression of MDS to Acute Myeloid Leukemia (AML), as well as by the positive preliminary clinical response. She believes this demonstrates the potential of mitochondrial augmentation, which was first highlighted at ASH in a presentation by Dr. Elad Jacoby in 2018.
Minovia will continue to develop its program to facilitate the introduction of this treatment modality into the MDS context, Dr. Yivgi-Ohana said.
The U.S. Food and Drug Administration has granted Fast Track and Orphan Drug Designations to MNV-201 for MDS. The FDA also granted Fast Track and Rare Pediatric Disease Designation for Pearson Syndrome.
Minovia also announced it has entered into a definitive business combination agreement with Launch One Acquisition Corp. (Nasdaq: LPAA), a publicly traded special purpose acquisition company. Upon closing, which is projected for early 2026, the combined company will operate as Minovia Therapeutics and trade on Nasdaq under a new ticker symbol.
Myelodysplastic Syndromes (MDS) are defined by ineffective hematopoiesis resulting in blood cytopenia, and clonal instability with a risk of evolution to AML. The median age at diagnosis of MDS is about 70 years. Minovia developed novel blood biomarkers to measure mitochondrial health and has demonstrated that MDS is an age-related mitochondrial disease. Minovia is conducting a Phase Ib study of MNV-201 in low-risk MDS patients, with six out of the expected nine patients already dosed.
MNV-201 is a cell therapy that uses Minovia’s Mitochondrial Augmentation Technology (MAT) to add healthy, energy-producing mitochondria into a patient’s own stem cells — aiming to restore organ function and improve health. In early-stage clinical studies, MAT has demonstrated a strong safety profile and signs of multi-system benefit in patients with Pearson Syndrome, including improvements in growth, muscle function, hematologic stability, and improved quality of life.
Minovia Therapeutics, chaired by John Cox, is working on treatments to replace dead or defective mitochondria with new healthy mitochondria, helping people with mitochondrial diseases and fighting aging. Minovia’s main treatment, MNV-201, is being tested for Pearson Syndrome and Myelodysplastic Syndrome. Minovia is also developing ways to help people live longer, healthier lives. Minovia operates a GMP facility in Haifa, Israel, and plans to expand operations to the U.S.
Launch One Acquisition Corp. is led by experienced leaders who want to support game-changing solutions. Jurgen van de Vyver can be contacted at jurgen@launchpad.vc or +1-510-692-9600.
Contact:
Minovia Therapeutics Ltd.
Natalie Yivgi Ohana, Co-Founder and CEO
+972-74-7039954
info@minoviatx.com
Jurgen van de Vyver
jurgen@launchpad.vc
+1-510-692-9600
Dave Gentry, CEO
RedChip Companies
+1-407-644-4256
LPAA@redchip.com
Jules Abraham
Managing Director, Communications
CORE IR
1-212-655-0924
Julesa@coreir.com
Source: Minovia Therapeutics
